CoChat
Sign Up
Cited by 187Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCancer-related cognitive impairment studies

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals

Open access
Fandos, Noelia, Pérez‐Grijalba, Virginia, Pesini, Pedro, Olmos, Salvador, Bossa, Matías, Villemagne, Victor L., Doecke, James, Fowler, Christopher, Masters, Colin L., Sarasa, Manuel, AIBL Research Group·2017·Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
DOI 10.1016/j.dadm.2017.07.004PMC PMC5602863
Open this paper in CoChat — free accountOpen PDF

Abstract

Introduction: Plasma amyloid β (Aβ) peptides have been previously studied as candidate biomarkers to increase recruitment efficiency in secondary prevention clinical trials for Alzheimer's disease. Methods: Free and total Aβ42/40 plasma ratios (FP42/40 and TP42/40, respectively) were determined using ABtest assays in cognitively normal subjects from the Australian Imaging, Biomarker and Lifestyle Flagship Study. This population was followed‐up for 72 months and their cortical Aβ burden was assessed with positron emission tomography. Results: Cross‐sectional and longitudinal analyses showed an inverse association of Aβ42/40 plasma ratios and cortical Aβ burden. Optimized as a screening tool, TP42/40 reached 81% positive predictive value of high cortical Aβ burden, which represents 110% increase over the population prevalence of cortical Aβ positivity. Discussion: These findings support the use of plasma Aβ42/40 ratios as surrogate biomarkers of cortical Aβ deposition and enrichment tools, reducing the number of subjects submitted to invasive tests and, consequently, recruitment costs in clinical trials targeting cognitively normal individuals.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.dadm.2017.07.004

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Box-and-whisker plots of plasma markers with regards to categorical Aβ-PET status (Aβ+ or Aβ−) measurements at each visit. (A) TP42/40, for visualization purposes three outliers (of the 236 valid measurements) with TP42/40 values between 0.19 and 0.54 were discarded. (B) BP42/40. (C) FP42/40, for visualization purposes three outliers (of the 217 valid measurements) with FP42/40 values between 0.19 and 0.29 are not shown. See data in Table 1. Abbreviations: BP, amyloid peptide bound to plasma; FP, free in plasma; TP, total amyloid β in plasma.
Fig. 1 Box-and-whisker plots of plasma markers with regards to categorical Aβ-PET status (Aβ+ or Aβ−) measurements at each visit. (A) TP42/40, for visualization purposes three outliers (of the 236 valid measurements) with TP42/40 values between 0.19 and 0.54 were discarded. (B) BP42/40. (C) FP42/40, for visualization purposes three outliers (of the 217 valid measurements) with FP42/40 values between 0.19 and 0.29 are not shown. See data in Table 1. Abbreviations: BP, amyloid peptide bound to plasma; FP, free in plasma; TP, total amyloid β in plasma.CC BY-NC-ND · PubMed Central
Fig. 2 Box-and-whisker plot of changes in the SUVR/BeCKeT along the follow-up for subjects with low or high baseline TP42/40 plasma ratio. Each point represents the change in each individual in SUVR/BeCKeT at visit month 18 (m18, blue), m36 (green), m54 (red), or m72 (cyan), with respect to the baseline SUVR/BeCKeT in APOE ε4 noncarriers (A) and APOE ε4 carriers (B). In (A or B), left panel contains the individuals with low (<the population median) TP42/40 levels at baseline (m18) and right panel the individuals with high (≥the population median) TP42/40 levels at baseline (m18). Note that in those individuals with low baseline TP42/40, average change in SUVR/BeCKeT significantly increased over visits, whereas in those with high baseline TP42/40 there was almost no change in the SUVR/BeCKeT during the follow-up. Similar figures are also obtained for the other markers FP42/40 and BP42/40 (see Table 3). Abbreviations: APOE, apolipoprotein E; BP, amyloid peptide bound to plasma; FP, free in plasma; TP, total amyloid β in plasma.
Fig. 2 Box-and-whisker plot of changes in the SUVR/BeCKeT along the follow-up for subjects with low or high baseline TP42/40 plasma ratio. Each point represents the change in each individual in SUVR/BeCKeT at visit month 18 (m18, blue), m36 (green), m54 (red), or m72 (cyan), with respect to the baseline SUVR/BeCKeT in APOE ε4 noncarriers (A) and APOE ε4 carriers (B). In (A or B), left panel contains the individuals with low (<the population median) TP42/40 levels at baseline (m18) and right panel the individuals with high (≥the population median) TP42/40 levels at baseline (m18). Note that in those individuals with low baseline TP42/40, average change in SUVR/BeCKeT significantly increased over visits, whereas in those with high baseline TP42/40 there was almost no change in the SUVR/BeCKeT during the follow-up. Similar figures are also obtained for the other markers FP42/40 and BP42/40 (see Table 3). Abbreviations: APOE, apolipoprotein E; BP, amyloid peptide bound to plasma; FP, free in plasma; TP, total amyloid β in plasma.CC BY-NC-ND · PubMed Central
Fig. 3 Comparison of the performance on PPV for three different classifiers as a function of the threshold value. In red, classifier including only the plasma marker log(TP42/40). In blue, classifier including age + APOE ε4 variables. In pink, classifier with all previous variables. The thick line represents the median value of the performance, and the thin dashed lines represent the 5th and 95th percentile values. Abbreviations: APOE, apolipoprotein E; PPV, positive predictive value; TP, total Aβ in plasma.
Fig. 3 Comparison of the performance on PPV for three different classifiers as a function of the threshold value. In red, classifier including only the plasma marker log(TP42/40). In blue, classifier including age + APOE ε4 variables. In pink, classifier with all previous variables. The thick line represents the median value of the performance, and the thin dashed lines represent the 5th and 95th percentile values. Abbreviations: APOE, apolipoprotein E; PPV, positive predictive value; TP, total Aβ in plasma.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

Sorted by citations

See all 187

Related

See all

Metadata

Authors
Fandos, N., Pérez‐Grijalba, V., Pesini, P., Olmos, S., Bossa, M., Villemagne, V. L., Doecke, J., Fowler, C., Masters, C. L., Sarasa, M., & AIBL Research Group
Affiliations
  • R&amp;D Department Araclon Biotech Ltd. Zaragoza Spain
  • Universidad de Zaragoza (ES)
  • The University of Melbourne (AU)
  • Commonwealth Scientific and Industrial Research Organisation (AU)
Corresponding author
Pesini, Pedro
ORCID
Venue
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Publisher
Wiley
Published
2017-01
Volume
8
Issue
1
Pages
179-187
ISSN
2352-8729 (ISSN-L)
DOI
10.1016/j.dadm.2017.07.004
PMC
PMC5602863
OpenAlex
W2750795037
Cited by
187
References
52
Citations by year
2026: 9 · 2025: 20 · 2024: 22 · 2023: 27 · 2022: 20 · 2021: 32 · 2020: 23 · 2019: 18 · 2018: 16
FWCI
12.81
Type
journal article
Language
en
Open access
Licence
Locations
  • Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • VUBIR (Vrije Universiteit Brussel) (submittedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
Keywords
amyloid-beta, Alzheimer's disease biomarkers, cognitively normal individuals, clinical trial recruitment, screening tool, positron emission tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review